GCM
VIR icon

Graham Capital Management’s Vir Biotechnology VIR Stock Holding History

Graham Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,120
Closed -$368K – 1531
2026
Q1 		$368K Buy
+41,120
New +$328K 0.01% 728
2025
Q3 		– Sell
-234,614
Closed -$1.18M – 1671
2025
Q2 		$1.18M Buy
234,614
+119,499
+104% +$641K 0.02% 536
2025
Q1 		$746K Buy
115,115
+33,865
+42% +$301K 0.01% 647
2024
Q4 		$596K Buy
81,250
+45,335
+126% +$358K 0.01% 674
2024
Q3 		$269K Buy
35,915
+23,321
+185% +$203K ﹤0.01% 818
2024
Q2 		$112K Buy
+12,594
New +$121K ﹤0.01% 935
2024
Q1 		– Sell
-24,254
Closed -$244K – 1315
2023
Q4 		$244K Sell
24,254
-29,249
-55% -$267K 0.01% 785
2023
Q3 		$501K Buy
+53,503
New +$763K 0.01% 564
2022
Q4 		– Sell
-21,926
Closed -$422K – 1366
2022
Q3 		$422K Buy
+21,926
New +$557K 0.02% 798
2022
Q2 		– Sell
-13,555
Closed -$348K – 1255
2022
Q1 		$348K Buy
+13,555
New +$402K 0.01% 684

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Graham Capital Management's VIR Position: Q2 2026 in Review

Graham Capital Management sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 41,120 shares — an estimated $368K sold.

Graham Capital Management first reported a position in VIR in Q1 2022 and held it in 10 quarters. The position peaked at $1.18M in Q2 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Graham Capital Management reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 41,120 Vir Biotechnology shares in Q2 2026, an estimated $368K.
  • Graham Capital Management first reported a position in Vir Biotechnology in Q1 2022 and held it in 10 quarters.
  • Graham Capital Management's Vir Biotechnology position peaked at $1.18M in Q2 2025.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.